Seattle Genetics | SGEN


Peers Price Chg Day Year Date
Takeda 4,642.00 68.00 1.49% 8.89% Sep/08
Astellas Pharma 1,722.00 21.00 1.23% -5.12% Sep/08
Eisai 5,316.00 179.00 3.48% -7.13% Sep/08
Daiichi Sankyo 3,674.00 53.00 1.46% -36.37% Sep/08
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Bayer 28.16 -0.42 -1.47% -1.83% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.26 0.12 0.25% -2.58% Sep/08
Celldex Therapeutics 22.87 0.09 0.40% -47.74% Sep/05
Exelixis 37.88 0.50 1.34% 50.62% Sep/05
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Insmed 145.10 2.57 1.80% 104.25% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
MacroGenics 2.00 0.06 3.09% -38.46% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Teva Pharmaceutical Industries 6,362.00 87.00 1.39% -5.45% Sep/07
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05
Xencor 8.55 0.18 2.15% -47.16% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US100 23719 19.43 0.08% 27.11% Sep/08

Seattle Genetics traded at $228.74 this Wednesday December 13th, decreasing $0.16 or 0.07 percent since the previous trading session. Looking back, over the last four weeks, Seattle Genetics lost 6.91 percent. Over the last 12 months, its price rose by 73.22 percent. Looking ahead, we forecast Seattle Genetics to be priced at 226.84 by the end of this quarter and at 221.24 in one year, according to Trading Economics global macro models projections and analysts expectations.

Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.